Veeva: Clinical Trial Platform Monopoly With Huge Untapped Opportunities (NYSE:VEEV)

JHVEPhoto Since I presented my ‘Strong Buy’ thesis for Veeva Systems (NYSE:VEEV) in June 2023, their stock price has surged by 21%. I discussed their data analytics and AI capabilities in the healthcare industry. They guide 15.5% revenue growth and 27% adjusted operating income growth for FY25. Veeva clinical platform connects clinical operations and data…

Read More

Sea: TikTok/GoTo’s Monopoly May Chip Away Market Share (NYSE:SE)

pick-uppath We previously covered Sea Limited (NYSE:SE) in September 2023, discussing its promising prospects in Indonesia attributed to the immediate ban of TikTok’s S-commerce platform. We had reckoned that TikTok’s estimated 2023 GMV of $8.4B might be up for grabs, allowing pure-play e-commerce companies like SE’s Shopee to benefit, naturally triggering our reiterated Buy rating….

Read More